US$ 24.14
wegovy semaglutide Tablets for Weight Management Novo Nordisk wins EU approval
Description
R.LewisM

Average weight loss reached 19.7% at the 8mg dose over 48 weeks
The FDA does not recommend routine calcitonin measurement or thyroid ultrasound screening, as these have uncertain value and are not recommended for patients taking GLP-1 receptor agonists

FDA has expressed concerns regarding product quality, misleading promotional claims, API sourcing, and reduced shortage-related justifications